Key Highlights
- H1 2026 Revenue reached €10,724 million, up 6.1% on a currency-neutral basis, with comparable operating profit up 8.1%.
- Comparable Diluted Earnings per Share rose 10.6% currency-neutral to €2.20, though shares fell about 4.3% on results day.
- Second-quarter revenue growth slowed to 2.5% reported, with revenue per unit case up just 0.1%, signalling fading pricing power.
- Management reaffirmed rather than raised full-year guidance, citing a challenging consumer environment and Middle East-related cost uncertainty.
- A €1 billion share buyback continues, with €593 million completed by 31 July 2026.
The world's largest Coca-Cola bottler delivered mid-single-digit revenue growth and double-digit earnings per share growth in the first half of 2026. Yet the shares slipped from an all-time high as investors focused on the outlook.
On paper, Coca-Cola Europacific Partners (LSE:CCEP) gave the market plenty to like when it reported half-year results for the six months to 3 July 2026. Revenue rose, operating profit expanded faster than sales, and comparable earnings per share climbed at a double-digit clip. Yet the London-listed shares, having touched an all-time high in the run-up to the numbers, fell around 4.3% to 7,710p on the day. The disconnect between solid trading and a soft share reaction is the story worth unpacking.
What happened
CCEP, the world's largest Coca-Cola bottler by revenue, sells across Western Europe and its Asia-Pacific and Indonesian (API/APS) territories following its 2021 Acquisition of Coca-Cola Amatil. For the first half, the group reported revenue of €10,724m, up 4.4% on a reported basis and 6.1% on a currency-neutral (comparable) basis. Comparable operating profit reached €1,481m, up 8.1% currency-neutral, while comparable diluted earnings per share rose 10.6% currency-neutral to €2.20. Reported diluted EPS came in at €2.17. The board declared an Interim Dividend of €0.82 per share.
That combination — revenue growth of roughly 6%, Operating Leverage and double-digit EPS growth — squarely matches the "revenue and EPS growth" framing. So does the cautious market response.
Why it matters
Coca-Cola Europacific Partners (LSE:CCEP) is a defensive, cash-generative staple that many UK income investors hold as ballast. When a Business of this quality grows earnings by double digits and still sees its shares sold off, it signals that expectations, rather than execution, are doing the heavy lifting. The shares had run to a record before the update, so the pullback looks as much like profit-taking on a demanding valuation as any verdict on the half itself. For a stock that trades on its reliability, the market's message was that "good" was already in the price.
The numbers investors need to know
Volumes rose 2.2% on a days-adjusted basis to 2,041m unit cases, split between Europe (+1.6%) and the API/APS territories (+3.5%) — evidence that pricing, not just Volume , drove the Top Line . Comparable free Cash Flow was €435m in the half, with the seasonal skew towards the second half as usual.
The more revealing detail sat beneath the headline. Second-quarter revenue growth slowed to 2.5% reported (3.3% currency-neutral), and revenue per unit case edged up just 0.1% in the quarter. After several years in which price/mix powered growth, that deceleration matters: it suggests the pricing lever is tiring as Inflation cools and consumers resist further increases.
On Market Value : at 7,710p and roughly 450m shares in issue, CCEP is worth around £35bn — an approximation derived from the quoted price, not a company-reported figure.
What management has said
Chief executive Damian Gammell struck a confident but measured tone. He said CCEP had "delivered a strong first half, with balanced revenue growth, continued share gains and disciplined cost and Cash Management ." He also flagged that the consumer environment "remained challenging, while the full impact of the conflict in the Middle East was uncertain" — a nod to both Demand softness and input-cost risk.
Crucially, management reaffirmed rather than raised full-year guidance. For 2026 the group continues to target comparable, currency-neutral revenue growth of 3–4%, operating profit growth of about 7%, cost of sales per unit case growth of around 1.5%, Capital Expenditure of roughly 5% of revenue, comparable free cash flow of at least €1.7bn and a dividend Payout Ratio of about 50%. The €1bn share buyback continues, with €593m completed by 31 July.
Market and analyst reaction
The share-price move told its own story: a fall of about 4.3% to 7,710p on the LSE, from what had been an all-time high. Coverage attributed the slip to the decision to reaffirm — rather than upgrade — full-year targets, combined with profit-taking after a strong run. Management pointed to two second-half headwinds: six fewer selling days than the first half, and commodity-cost pressure linked partly to the Middle East situation, expected to weigh more heavily in H2.
Broker sentiment coming into the results remained constructive: Barclays carried an "overweight" rating and UBS a "buy", with a median price target of $109.50 across a small group of analysts on the US-listed line. Readers should treat those pre-results ratings as expectations, not confirmation that views held after the print.
The bigger picture
CCEP remains a structurally attractive Franchise : a near-monopoly bottler for one of the world's strongest Brand portfolios, with pricing power, entrenched distribution and a management team that has delivered on its Amatil integration promises. The strategic emphasis on cost discipline, cash generation and — per its own commentary — greater use of AI and automation fits the template of a mature staple squeezing efficiency from scale. But the growth algorithm is shifting from price-led to volume-and-mix-led, and that transition is rarely smooth.
Bull case
For the optimists, the half delivered exactly what the model promises: dependable low-to-mid single-digit revenue growth converting into faster profit and double-digit EPS growth, underpinned by continued share gains and a €1bn buyback that steadily shrinks the share count. A ~50% payout, at least €1.7bn of free cash flow guided for the year, and API/APS territories still growing volumes faster than mature Europe give the story a credible growth Kicker on top of a defensive core.
Risks and bear case
The bears will point to the Q2 slowdown, near-flat revenue per case and a consumer that management itself calls challenging. If pricing can no longer do the work, volumes must — and in soft European markets that is not guaranteed. Second-half cost headwinds, fewer selling days and Commodity Volatility could squeeze margins just as comparatives toughen. On a full valuation near record highs, any wobble in the growth narrative leaves little room for error, as the post-results dip demonstrated.
What investors should watch next
Key markers from here: whether Q3 volumes and revenue per case stabilise or slow further; how commodity and input costs track into the second half; progress on the buyback; and, above all, whether management holds, lifts or trims full-year guidance at the next update. Any move on the ~7% operating-profit and ≥€1.7bn free-cash-flow targets will set the tone.
Outlook
CCEP's first half was, by most measures, a good one: growing revenue, expanding margins and double-digit EPS growth from a high-quality, cash-generative business. The caution lay not in the results but in the setup — a record-high share price, a reaffirmed rather than raised outlook, and second-half cost and demand risks that leave the market wanting proof before it pays more. the numbers are confirmed, but the debate over what they are worth is very much open.



_11_18_2026_13_53_59_733490.jpg)


Please wait processing your request...